Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06544629 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imjudo & Imfinzi PMS

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Feb 28, 2029 → Dec 30, 2029
See other at-risk trials from AstraZeneca

Record History

  1. Primary and study completion pushed from Feb 28, 2029 to Dec 30, 2029 Primary endpoints: details revised at 1 of 1 entry · Eligibility criteria expanded, about 4 words Show 2 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 4 words
  2. Re-verified, no change to tracked fieldsv5
  3. Site details revised at 2 of 6 sitesv4
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 6 · Start date changed from estimate of Apr 1, 2025 to Apr 14, 2025v3 Show 2 more changesShow less
    • Study sites: 0 to 6
    • Start date changed from estimate of Apr 1, 2025 to Apr 14, 2025
  5. Start date: Dec 30, 2024 to Apr 1, 2025v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.
Trial Details
NCT Number NCT06544629
Lead Sponsor AstraZeneca
Conditions Hepatocellular Carcinoma
Enrollment 246 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov